This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Philip Seeman, MD, PhD; Hyman B. Niznik, PhD; Hong-Chang Guan, MD
Departments of Psychiatry and Pharmacology Medical Sciences Building University of Toronto Toronto, Ontario, Canada M5S 1A8

Arch Gen Psychiatry. 1990;47(12):1170-1172.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In schizophrenia, the brain reveals elevated densities of dopamine D₂ receptors whether or not the patients have received neuroleptic medications.^1-3 In addition, the left putamen in schizophrenia shows D₂ to be elevated by 2.8 pmol/mL, significantly different from the right side, but nonsignificantly elevated by 3.2 pmol/mL compared with controls.⁴

It has been puzzling that these unilateral elevations of 2.8 to 3.2 pmol/mL, seen with [¹¹C]raclopride, are less than the bilateral D₂ elevations of 12 and 25 pmol/mL^2,3 found in never-medicated patients measured with radioactive spiperone compounds. There are many factors that may explain such differences.⁵ We report herein, using human tissues, that the density of D₂ is underestimated by radioactive raclopride in the presence of dopamine. Furthermore, when the cerebellum is used as baseline, the apparent value for the total D₂ density is artificially . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?